Your shopping cart is empty

Subscriber login

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug Industry Daily > Top-Line Results Look Good for Lilly Type 2 Diabetes Drug Dulaglutide

Drug Industry Daily

Oct. 23, 2012 | Vol. 11 No. 208

Top-Line Results Look Good for Lilly Type 2 Diabetes Drug Dulaglutide

Eli Lilly’s once-weekly Type 2 diabetes candidate dulaglutide met its primary endpoint for hemoglobin A1c reduction in top-line results from three studies.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
Email This Article
RSS
Free Trial
Archives
Sample PDF

Lilly Halts Phase III Trial of Non-Hodgkin’s Lymphoma Candidate The Buzz FDA Urges Risk-Based Immunogenicity Assessments for Therapeutic Protein Products Biogen Idec Sees Positive Top-Line Results for Peginterferon Beta-1a in Multiple Sclerosis

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.